Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy

Conclusions: The risks of hormone therapy should be assessed on an individual basis, with consideration of age, type of hormone therapy, dose, duration of use, regimen, route, and prior exposure. Systemic hormone therapy is not recommended in breast cancer survivors, whereas vaginal low-dose estrogen appears safe. Hormone therapy may be used by endometrial, cervical, and ovarian cancer survivors with low-risk, non-estrogen-receptor–positive subtypes. Video Summary:http://links.lww.com/MENO/A516.
Source: Menopause - Category: OBGYN Tags: Review Article Source Type: research